Patient Access: Moderate to Severe Plaque PsO | TREMFYA® (guselkumab) HCP

AFTER CONSIDERING THE EFFICACY AND SAFETY OF TREMFYA® FOR PATIENTS WITH MODERATE TO SEVERE PLAQUE PsO

Choose TREMFYA®.

Get TREMFYA®.

Nearly

100%

of commercially insured patients have preferred* access for TREMFYA®†‡

A dedicated TREMFYA withMe Guide can work one-on-one with eligible, non–commercially insured patients to answer questions about prescription fulfillment and help find financial assistance options.

TREMFYA withMe is limited to education for patients about TREMFYA®, its administration, and/or their disease, and is not intended to provide medical advice, replace a treatment plan from the patient’s doctor or nurse, or provide case management services.

Source: Managed Markets Insight & Technology, LLCTM, a trademark of MMT, as of March 2023.

*Preferred means TREMFYA® is available on the plan’s formulary and may require a step edit.

Within 2% of actual access.

This may not represent 100% of lives due to data limitations.

Local coverage options for TREMFYA®

Explore TREMFYA® access options in your area
TREMFYA® access has changed in many regions–see where it has preferred first-line access without biologic step edits* by entering a ZIP Code below.

 

*Requiring no step edits indicates that a drug will be given first-line biologic access and will not require stepping through other biologic therapies.

The information provided is not a guarantee of coverage or payment (partial or full). Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures. This document is presented for informational purposes only and is not intended to provide reimbursement or legal advice, nor does it promise or guarantee coverage, levels of reimbursement, payment, or charge. It is not intended to increase or maximize reimbursement by any payer. Laws, regulations, and policies concerning reimbursement are complex and are updated frequently. While we have made an effort to be current as of the issue date of this document, the information may not be as current or comprehensive when you view it. Please refer to the applicable plan’s website, or contact the plan for more information about coverage or any restrictions or prerequisites that may apply. We strongly recommend you consult the payer organization for its reimbursement policies. All information is subject to change. Nothing herein may be construed as an endorsement, approval, recommendation, representation, or warranty of any kind by any plan or insurer referenced herein. This communication is solely the responsibility of Janssen Biotech, Inc.

cp-426157v1

Back to Top